Polymyxins are polycationic antimicrobial peptides that are currently the last-resort
antibiotics for the treatment of multidrug-resistant, Gram-negative bacterial infections. The …

Polymyxins have recently been re-introduced into the therapeutic arsenal to combat
infections caused by multidrug-resistant Gram-negative bacteria. However, the emergence …

Background: Infections caused by multi-drug-resistant Gram-negative bacteria, particularly
Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, that …

Acinetobacter baumannii is recognized as a clinically significant pathogen causing a wide
spectrum of nosocomial infections. Colistin was considered a last-resort antibiotic for the …

Abstract Background Multidrug-resistant Gram-negative bacteria (MDRGN), including
extended-spectrum β-lactamases (ESBLs) and multidrug-resistant glucose-nonfermenting …

Acinetobacter baumannii is an opportunistic pathogen associated with nosocomial and
community infections of great clinical relevance. Its ability to rapidly develop resistance to …

Acinetobacter baumannii is an important opportunistic nosocomial pathogen often resistant
to multiple antibiotics classes. Colistin, an “old” antibiotic, is now considered a last-line …

Emerging multidrug-resistant (MDR) nosocomial pathogens are a great threat. Polymyxins,
an old class of cationic polypeptide antibiotic, are considered as last-resort drugs in treating …

Acinetobacter baumannii is an opportunistic pathogen that poses an increasing threat in the
health-care community. Colistin is one of the promising options for treatment of multidrug …

Acinetobacter baumannii can acquire resistance to colistin via complete loss of
lipopolysaccharide (LPS) biosynthesis due to mutations in the lpxA, lpxC and lpxD genes …